NN9535-4447 Epidemiological assessment of the risk for pancreatic cancer associated with the use of semaglutide in patients with type 2 diabetes- A cohort study based on Nordic registry data

First published 30/09/2020

Last updated 23/04/2024

EU PAS number:

EUPAS37258

Study

Ongoing

Documents

Study protocol

Study results

Study report

First Progress Report NN9535-4447

English (224.86 KB - PDF)View document

Progress report NN9535-4447_3

English (293.98 KB - PDF)View document

_ Regulatory Progress Report NN9535-4447 progress report_2

English (221.29 KB - PDF)View document

Other information

Study, other information

_ Regulatory Progress Report NN9535-4447 progress report_2.pdf

English (221.29 KB - PDF)View document

Progress report NN9535-4447_3.pdf

English (293.98 KB - PDF)View document

ENCePP Seal

This study has been awarded the ENCePP seal

ENCePP Seal documents

Conflicts of interest of investigators

2020-0065 Declaration of Interests

English (903.89 KB - PDF)View document

Composition of steering group and observers

ENCePP Seal Composition of Steering Group and Observers

English (7.63 KB - PDF)View document

Secondary tabs